Investors focused on the Medical space have likely heard of HMS Holdings , but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
HMS Holdings is a member of the Medical sector. This group includes 757 individual stocks and currently holds a Zacks Sector Rank of #5. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. HMSY is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for HMSY's full-year earnings has moved 17.65% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
According to our latest data, HMSY has moved about 86.73% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of 6.99% on a year-to-date basis. As we can see, HMS Holdings is performing better than its sector in the calendar year.
Breaking things down more, HMSY is a member of the Medical Info Systems industry, which includes 21 individual companies and currently sits at #117 in the Zacks Industry Rank. On average, this group has gained an average of 10.42% so far this year, meaning that HMSY is performing better in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track HMSY. The stock will be looking to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Investors focused on the Medical space have likely heard of HMS Holdings , but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
HMS Holdings is a member of the Medical sector. This group includes 757 individual stocks and currently holds a Zacks Sector Rank of #5. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. HMSY is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for HMSY's full-year earnings has moved 17.65% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
According to our latest data, HMSY has moved about 86.73% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of 6.99% on a year-to-date basis. As we can see, HMS Holdings is performing better than its sector in the calendar year.
Breaking things down more, HMSY is a member of the Medical Info Systems industry, which includes 21 individual companies and currently sits at #117 in the Zacks Industry Rank. On average, this group has gained an average of 10.42% so far this year, meaning that HMSY is performing better in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track HMSY. The stock will be looking to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>